APR 10, 2019 01:30 PM PDT

Detection and Interpretation of Complex Myeloid Leukemia Mutations

SPONSORED BY: QIAGEN
C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Global Product Manager of Personalized Healthcare/Oncology at QIAGEN
    Biography
      Dr. Véronique Laloux is Senior Global Product Manager of Personalized Healthcare/Oncology at QIAGEN. With 15 years of experience working for molecular diagnostic industries in sales, marketing and product management roles, Véronique is responsible for onco-hematology content development of PCR (ipsogen brand) and GeneReader NGS System (QIAact brand) assays. Véronique holds a Ph.D. in Molecular Biology and Biochemistry from University Pierre et Marie Curie, Paris 6, France.
    • Product Owner of QIAGEN Clinical Insight (QCI™) Intepret
      Biography
        Dr. Beate Litzenburger is the product owner of QIAGEN Clinical Insight (QCI™) Intepret. Prior to joining the QIAGEN team, Dr. Litzenburger led clinical decision support for several next generation sequencing research protocols at MD Anderson Cancer Center. In this role, Dr. Litzenburger was responsible for providing alteration interpretation, drug, and clinical trial options to clinicians. Dr. Litzenburger received her Ph.D. in molecular genetics from the University of Aachen in Germany and was a National Cancer Institute-supported post-doctoral fellow in the Department of Clinical Cancer Prevention at MD Anderson Cancer Center.

      Abstract:

      Myeloid leukemias encompass a group of different diseases that include myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). These diseases are driven by somatic mutations acquired in 20-30 key genes. Given the genetic complexity of these heterogeneous disorders, there is an increasing need for molecular identification of key mutations across all of these genes. 

      In this webinar we will introduce two solutions for the detection and interpretation of mutations associated with myeloid leukemias.

      In the first half we introduce an integrated Sample to Insight NGS clinical research workflow for detection of myeloid leukemia mutations.  The QIAact Myeloid DNA UMI Panel in combination with the QIAGEN GeneReader™ NGS System provides a complete solution that can simultaneously test for around 9000 variants in 25 genes with reported relevance to clonal myeloid malignancy. The incorporation of unique molecular index (UMI) technology enables detection of even low-frequency variants, including JAK2 and KIT variants below the 1% variant allele frequency (VAF) and the KIT D816V mutation at 0.4% VAF. Accurate reporting of usually challenging-to-detect mutations such as the large CALR Type 1 (52 bp deletion), FLT3 ITDs (with identified insertion site), and GC-rich sequences such as in the CEBPA gene, are also possible due to the pairing of this digital sequencing approach with optimized bioinformatics. We will present clinical research data to show the successful detection and reporting low-frequency variants and challenging alterations with this complete assay.

      In the second half we present a bioinformatics solution for the clinical interpretation of somatic myeloid leukemia mutations. Cancer laboratories need rapid and reliable interpretation of identified genomic alterations. One of the challenges they face is producing standardized, reproducible interpretation and reporting of the most current and actionable information. QIAGEN Clinical Insight (QCI™) Interpret allows labs to deliver evidence-based, actionable insights. We will discuss the methodology and benefits of automating guidelines (AMP/ASCO/CAP and ACMG/AMP) for vetting somatic cancer alterations for actionability and pathogenicity in the same workflow while providing full transparency to the underlying evidence.

      Learning Objectives: 

      1. Understand the value of a tailored integrated Sample to Insight NGS workflow for the detection of complex mutations in myeloid leukemia
      2. Understand the value of standardized and consistent interpretation, especially for complex diseases like myeloid malignancies


      Show Resources
      You May Also Like
      FEB 26, 2019 09:00 AM PST
      C.E. CREDITS
      FEB 26, 2019 09:00 AM PST
      DATE:  February 26, 2019TIME:   9:00am PST, 12:00pm EST In an era of increasingly high-throughput, large-scale biology, with companies, government and non-prof...
      NOV 15, 2018 10:00 AM PST
      C.E. CREDITS
      NOV 15, 2018 10:00 AM PST
      DATE:  November 15, 2018TIME:  10:00am PT, 1:00pm ET Multiplex fluorescence immunohistochemistry offers a window into the biology of human disease, enabling the ana...
      MAR 26, 2019 02:00 PM PDT
      C.E. CREDITS
      MAR 26, 2019 02:00 PM PDT
      DATE:  March 26, 2019TIME:  2:00pm PDT, 5:00pm EDT  Prostate cancer is the second most common form of cancer in males, affecting one in eight men by the time t...
      NOV 21, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      NOV 21, 2019 09:00 AM PST
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: November 21, 2019TIME: 9:00am PST, 12:00pm EST Multiple Myeloma is a disease of terminally differentiated plasma cells with the massive production of monoclonal immunoglobu...
      JAN 22, 2019 07:00 AM PST
      C.E. CREDITS
      JAN 22, 2019 07:00 AM PST
      DATE:    January 22, 2019TIME:    07:00am PST, 10:00am EST Molecular diagnostic tests are currently used for infectious disease testing due to t...
      MAY 16, 2019 12:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      C.E. CREDITS
      MAY 16, 2019 12:00 PM PDT
      Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
      DATE: May 07, 2019TIME: 10:00 AM PST Mesenchymal stem or stromal cells (MSCs) are a promising resource for cell-based therapies and are being tested in already registered phase...
      Loading Comments...
      Show Resources